On July 11, 2019 Biocure Technology Corp. ("CURE" or the "Company") (CSE:CURE; OTCQB: BICTF) BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Inc. ("CURE") reported that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK has issued 60,404 shares at $10.898 CAD per share for gross proceeds of $658,258.63 (Korean Won591,959,200 @$0.001112 CAD/KW per Bank of Canada Exchange Rate) (Press release, Biocure Technology, JUL 11, 2019, View Source [SID1234628755]). After the issuance of new BPK shares, CURE holds now 95.82% interest in BPK.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The net proceeds from the non-brokered private placement are intended to be used for general working capital and research and development.